Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17747018 | 0.92 | HDAC8 (0.43) | HDAC8KMT2APOLB | |
| SCHEMBL17747020 | 0.92 | HDAC8 (0.43) | HDAC8KMT2APOLB | |
| SCHEMBL17746996 | 0.92 | HDAC8 (0.43) | HDAC8KMT2APOLB | |
| SCHEMBL17746994 | 0.92 | HDAC8 (0.43) | HDAC8KMT2APOLB | |
| SCHEMBL20009696 | 0.89 | ACE (0.40) | HDAC8KMT2AACE | |
| SCHEMBL17747017 | 0.83 | CTSK (0.40) | KLK5 | |
| SCHEMBL17747019 | 0.83 | CTSK (0.40) | KLK5 | |
| SCHEMBL20009636 | 0.81 | KMT2A (0.39) | KMT2APOLBL3MBTL1HDAC2 | |
| SCHEMBL17746956 | 0.81 | NOD1 (0.44) | HDAC8KMT2AACE | |
| SCHEMBL17746953 | 0.81 | NOD1 (0.44) | HDAC8KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | HDAC8 1176/4885KMT2A 3513/4885POLB 2800/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | HDAC8 1176/4885KMT2A 3513/4885POLB 2800/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | HDAC8 1176/4885KMT2A 3513/4885POLB 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.